PubMed Health⌕ Search

Biomedical subjects

C Bailey

Publications and source records attributed to C Bailey.

At least 109 records · Page 6Linked to original sources
PubMed1981

A national trial on the treatment of invasive bladder cancer.

A new anti-cancer agent, misonidazole, is now available for investigational purposes. It is a radiation sensitiser, and a national trial is described for its use in the curative treatment of carcinoma of the bladder. The co-operation of doctors is sought in referring patients for this study.

Carcinoma↗
PubMed1978

Radiation myelitis following craniospinal irradiation with concurrent actinomycin-D therapy.

Two patients are presented who developed radiation myelitis as a complication of treatment for medulloblastoma. These patients had been entered onto a pilot study to evaluate the therapeutic efficacy of combined treatment with radiation therapy and actinomycin-D (AMD). AMD is a known radiation enhancer in all tissues but the nervous system. Both of these patients received a full course of cranio-spinal irradiation plus AMD 15 mcg/kg for the first five days of therapy. One patient developed myelitis at 4 months, and the other at 12 months after treatment. Both patients are surviving three years posttreatment without any evidence of recurrent disease. The myelitis in one patient has improved, and it is stable in the other patient. It is concluded that AMD enhances the effect of radiation therapy on the central nervous system. This has never been reported but is important to note now, since radiation enhancers are included in multimodal treatment regimens for a variety of malifnant conditions. Reduction of radiation dose may be necessary when large volumes of the nervous system are treated.

Adolescent↗
PubMed1978

Systolic time intervals in monitoring for anthracycline cardiomyopathy in pediatric patients.

Systolic time intervals are of value in measuring left ventricular function. The ratio of the pre-ejection period to the left ventricular ejection time (PEP/LVET) was determined serially in 60 children with cancer receiving anthracycline drugs. Measurements were examined for their predictive value in determining incipient anthracycline cardiomyopathy. An increase in the PEP/LVET ratio was not followed by clinical failure in the majority of patients. Of two patients who developed presumed anthracycline cardiomyopathy, only one demonstrated an increase in the ratio prior to going into heart failure. The value of the PEP/LVET ratio in children for predicting anthracycline cardiomyopathy appears limited, based on the results of this study.

Adolescent↗